A recent preprint available on the bioRxiv* preprint server discusses the antibody response to the nucleic acid vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) when administered to children aged 7-11 years.
Background
As SARS-CoV-2 spread rapidly worldwide, scientists responded with unprecedented efforts to develop effective vaccines.
With high rates of morbidity and mortality among the older population and those with underlying comorbidities, vaccine rollouts were prioritized to these groups at first and frontline essential workers.
